Trials / Completed
CompletedNCT00686582
An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 304 (actual)
- Sponsor
- Bavarian Nordic · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The study was preformed to evaluate the persistence of antibodies following vaccination with MVA-BN and to assess the immunological memory response induced by a booster vaccination with MVA-BN in subjects two years after their participation in trial POX-MVA-005 (NCT00316524) in which they had received one or two doses of MVA-BN.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IMVAMUNE | 1x 10E8\_TCID50 |
| BIOLOGICAL | IMVAMUNE | 1x 10E8\_TCID50 |
| PROCEDURE | Blood Draw Only |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2008-12-01
- Completion
- 2009-06-01
- First posted
- 2008-05-30
- Last updated
- 2019-03-13
- Results posted
- 2019-02-18
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00686582. Inclusion in this directory is not an endorsement.